pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›ACTEMRA
drug
save

ACTEMRA

updated 6mo ago
by Genentech Inc
community read0 votes

🐶 often sniffed alongside

top 8
  • tagApproval264 co-mentions · 72 sources
  • drugtocilizumab253 co-mentions · 73 sources
  • drugTYENNE16 co-mentions · 8 sources
  • drugRNS-608 co-mentions · 8 sources
  • companyFresenius Kabi USA LLC8 co-mentions · 8 sources
  • drugAVTOZMA8 co-mentions · 4 sources
  • companyCelltrion Inc4 co-mentions · 4 sources
  • companyChugai Pharmaceutical Co Ltd1 co-mentions · 1 sources

all catalysts(0)

nothing on the calendar yet

Trials studying ACTEMRA

  • phase3A Study to Test Obrixtamig Treatment in People With Different Types of Advanced Cancer Who Took Part in a Previous Study With Obrixtamignot yet recruitingn=68
  • phase2Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myelomarecruitingn=45
  • phase1A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemiarecruitingn=332
  • phase2A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myelomarecruitingn=200
  • phase2A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myelomaactive not recruitingn=90
  • phase3A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)recruitingn=340
  • phase1A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myelomarecruitingn=186
  • phase1A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)recruitingn=120

News(3)

  • Roche sets sights on FDA approval decision of July 2027 with updated eye drug data
    One year on from a mixed phase 3 readout, Roche has shared updated data from eye disease trials that could support FDA approval by July.
    fiercebiotech · 1mo ago
  • Fresenius Kabi Issues Nationwide Recall of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL Vials Due to Presence of Glass Particles
    FOR IMMEDIATE RELEASE – August 10, 2026 – LAKE ZURICH, Ill.— Fresenius Kabi, an operating company of the Fresenius Group, is recalling one lot of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL (…
    fda_medwatch · 3mo ago
  • Dr Silbermann on Clinical Trial Design Considerations in Multiple Myeloma
    Rebecca Silbermann, MD, MMS, outlines key trial design considerations in multiple myeloma, including supportive care measures and end point selection.
    onclive · 6mo ago
brand
ACTEMRA
generic
TOCILIZUMAB
Data sources
ClinicalTrials.gov
last refreshed 1h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?